Aura Bio AURA Q1 2026 Earnings Soft Quarter Raises Questions Altimmune ALT Edges Higher Testing Key Resistance After Recent Decline Saudi Arabia Halts New Consultant Contracts as Spending Constraints Intensify on Vision 2030 Projects